Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rezolute, Inc.

NASDAQ: RZLT · Life Sciences · 7 alerts · CIK 1509261

Rezolute, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.58Close, Nov 16
Market cap
$346M
Shares outstanding
96.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗

6:27 AM ET 8-K
Clinical Trial Data

Rezolute Clinical Trial Data

Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism. The study met its primary efficacy endpoint with 13 of 16 participants achieving at least a 50% reduction in glucose infusion rate, including 12 who completely discontinued IV glucose. The company expects to report full topline results in mid-December 2026 and engage with the FDA in Q1 2027.

Term
8 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.